Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network Study
Nine diabetes drugs show broadly similar benefits across patient groups, suggesting obesity and sex alone don't reliably predict which drug works best for individuals.
This large OHDSI-network study extending LEGEND-T2DM found limited evidence of heterogeneous treatment effects across 9 glucose-lowering drug classes in T2D, with only nominal signals of differential benefit (e.g., SGLT2i vs GLP-1 RA lower stroke risk in non-obese patients) that did not survive multiple testing correction. The hypothesis-generating findings suggest current evidence does not robustly support major personalized treatment changes based on obesity status or sex alone.
What the study was
- Study design
- Large-scale multi-database observational cohort study (6 data sources, OHDSI network)
- Population
- T2D patients initiating glucose-lowering therapies across 6 real-world databases
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Diabetes Obes Metab
Why it surfaced
Large multi-database OHDSI study for personalized T2D treatment; relevant background for cardiometabolic precision medicine pipeline.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.